Skip to main content

Vividion Therapeutics Expands Leadership Team with the Appointments of Fred Aslan, M.D., President and Chief Business Officer, and Larry Burgess, Ph.D., Head of Chemistry

September 25, 2018, San Diego, CA – Vividion Therapeutics, a biotechnology
company applying revolutionary proteomics and chemistry platforms to discover and
develop novel small molecule therapeutics, today announced the appointments of Fred
Aslan, M.D. as President and Chief Business Officer and Larry Burgess, Ph.D. as Head
of Chemistry.

“We are delighted to expand the Vividion family with these two high caliber individuals.
Vividion’s rapid generation of potent and selective small molecule leads against
undruggable targets presents a vast opportunity that requires a skilled team to
effectively deploy,” said Diego Miralles, Chief Executive Officer.

Dr. Aslan most recently was the founder and CEO of Adavium Medical, which he built
into a leading Brazilian medical device company, raising over US$50 million from
institutional investors. Prior to Adavium Medical, he was a full-time investor at Venrock,
a leading venture capital firm he joined in 2006, where he was involved with several
successful biotech and medical device companies. Dr. Aslan was a co-founder and
board member of Receptos Pharmaceuticals, a NASDAQ-listed biotech company,
which was subsequently acquired by Celgene for more than $7 billion. He also led
Venrock’s investment in Zeltiq, a NASDAQ-listed medical device company that was
acquired by Allergan for more than $2 billion. Prior to Venrock, he was Director of
Business Development and led Investor Relations at CuraGen, a NASDAQ-listed
oncology-focused biotech company, and was a strategy consultant with Boston
Consulting Group (BCG). He received a B.S. in Biology from Duke University, an M.D.
from Yale and an M.B.A. from Harvard.

“We are delighted to have Fred join our company. Throughout his career he has gained
significant experience in strategic financing and operational excellence,” stated Miralles.
“Fred’s talents enhance our ability to execute and finance the large number of program
opportunities created by Vividion’s unique platform.”

“I am excited to work with such a talented group of leaders, scientists, founders and
investors,” stated Fred Aslan. “I look forward to using my experience-set to help Vividion
unleash the full potential of its platform as we advance novel, impactful therapies to the

Dr. Burgess brings extensive scientific leadership and drug development experience to
Vividion. He previously served as the Vice President of Medicinal Chemistry for Array
BioPharma, where he helped to advance many discovery programs that resulted in
Investigational New Drug (IND) applications. The majority of those drugs are currently
being tested in patients or are approved. Prior to joining Array BioPharma, he was at
Amgen and Pfizer. Dr. Burgess received a B.S. in chemistry from the Georgia Institute
of Technology, a Ph.D. from the University of Texas and completed his postdoctoral
research at Colorado State University.

“Throughout his career Larry has demonstrated the exceptional scientific leadership and
execution skills that are needed to maximize the enormous potential of our platforms,”
said Miralles. “We believe we can transform the way in which small molecules are
discovered and can build clinical programs against targets that until now have remained
undruggable; he will be instrumental in helping us make that vision a reality.”
“I’m excited to join the Vividion family and help guide discovery and early development
efforts. These novel chemistry and proteomic technologies have enormous potential to
deliver high value clinical candidates,” said Dr. Burgess.